Structo: A Start-Up in 3D Printing for the Dental Industry Custom Case Solution & Analysis

Evidence Brief: Structo 3D Printing

1. Financial Metrics

• Product Pricing: OrthoForm priced at approximately $10,000; DentaForm (higher throughput) priced significantly higher to target large-scale dental labs.
• Market Valuation: Dental 3D printing market projected to reach $3.7 billion by 2021 (Exhibit 1).
• Funding: Raised Series A funding led by Wavemaker Partners and SEEDS Capital; seeking Series B to fund global expansion.
• Revenue Model: Hybrid model consisting of upfront hardware sales and recurring revenue from proprietary resin consumables.

2. Operational Facts

• Technology: Mask Stereolithography (MSLA) technology. Claims speeds up to 10x faster than traditional SLA printers.
• Throughput: DentaForm can print up to 10 dental models in 30 minutes.
• Manufacturing: Headquarters and primary assembly located in Singapore.
• Product Line: OrthoForm (desktop), DentaForm (industrial), and Elements (fully automated factory-in-a-box).
• Geography: Presence in Singapore, USA, UK, and Canada.

3. Stakeholder Positions

• Huub van Esbroeck (Founder/CEO): Focused on maintaining the technical lead in MSLA while transitioning from a hardware startup to an industry-specific solution provider.
• Dental Lab Owners: Primary customers; concerned with cost-per-part, ease of integration into existing digital workflows, and reliability.
• Competitors: Carbon 3D (high-end subscription model), Formlabs (low-cost desktop), and 3D Systems/Stratasys (industrial incumbents).
• Investors: Pressuring for rapid scaling in the North American and European markets to capture clear aligner growth.

4. Information Gaps

• Unit Economics: Exact margin breakdown between hardware sales and resin consumables is not disclosed.
• Customer Churn: Data on long-term retention of dental labs after the initial hardware purchase.
• IP Defense: Specifics on the strength of MSLA patents against potential workarounds by larger competitors like Carbon.

Strategic Analysis

1. Core Strategic Question

• Should Structo remain a horizontal hardware manufacturer or pivot to a vertically integrated dental solution provider to survive against better-capitalized incumbents?

2. Structural Analysis

• Competitive Rivalry: High. Formlabs dominates the low-end price point while Carbon 3D controls the high-end subscription market. Structo is caught in the middle.
• Bargaining Power of Buyers: Increasing. Large dental labs are consolidating and demanding lower per-arch costs.
• Threat of Substitutes: Direct-to-consumer aligner companies are bypassing traditional labs, potentially shifting the buyer profile from labs to centralized factories.
• Value Chain: The bottleneck is not just printing speed but the post-processing (washing and curing) and software integration.

3. Strategic Options

• Option A: Vertical Integration (The Solution Model). Develop proprietary software and automated post-processing to offer a complete end-to-end aligner production system.
  • Rationale: Increases switching costs and captures more value per customer.
  • Trade-offs: Requires significant R&D investment and complicates the sales cycle.
• Option B: Aggressive Geographic Expansion. Focus exclusively on the US and EU markets with the existing DentaForm and Elements printers.
  • Rationale: These regions represent the highest density of orthodontic spending.
  • Trade-offs: High customer acquisition costs and logistics overhead.
• Option C: OEM Licensing. License MSLA technology to established dental giants (e.g., Dentsply Sirona).
  • Rationale: Rapid scaling with minimal capital expenditure.
  • Trade-offs: Loss of brand equity and long-term margin potential.

4. Preliminary Recommendation

Structo must pursue Option A (Vertical Integration). Speed alone is a depleting asset. By integrating software and post-processing into the Elements platform, Structo moves from selling a tool to selling a factory. This creates a moat that hardware-only competitors cannot easily breach.

Implementation Roadmap

1. Critical Path

• Phase 1 (Months 1-3): Finalize API integrations with major intraoral scanner software (e.g., 3Shape, Itero) to ensure seamless data flow.
• Phase 2 (Months 4-6): Launch the Elements automated unit in the North American market through three flagship dental lab partnerships.
• Phase 3 (Months 7-12): Scale resin production capacity in regional hubs to reduce lead times and shipping costs for consumables.

2. Key Constraints

• Regulatory Compliance: FDA Class II certification for new resins is mandatory for US expansion and can take 6-12 months.
• Technical Support Talent: Industrial 3D printers require on-site maintenance. Recruiting and training field engineers in the US/EU is the primary bottleneck for scaling.

3. Risk-Adjusted Implementation Strategy

Focus initial 90-day efforts on the Elements platform specifically for the clear aligner segment. This segment has the highest tolerance for high-capital expenditure if it reduces labor costs. Avoid the general dentistry market (crowns/bridges) where Formlabs has a price advantage. Establish a US-based spare-parts warehouse before signing any contracts exceeding five units to mitigate downtime risks.

Executive Review and BLUF

1. BLUF

Structo must cease competing as a general-purpose 3D printer company. The technical advantage of MSLA speed is temporary and will be neutralized by incumbents within 24 months. Structo should pivot immediately to a vertical solution provider for the clear aligner industry. The focus must be the Elements platform. Success depends on automating the entire workflow—from scan to arch—rather than just the print phase. If the company fails to lock in large dental labs with an integrated software-hardware-resin stack now, it will be relegated to a niche hardware player with declining margins.

2. Dangerous Assumption

The analysis assumes that dental labs will continue to be the primary decision-makers. If the industry shifts toward direct-to-consumer companies performing their own printing in-house, Structo’s current sales channel and lab-focused features become obsolete.

3. Unaddressed Risks

4. Unconsidered Alternative

The team did not evaluate a Service Bureau Model. Instead of selling machines, Structo could operate its own high-speed printing centers, selling finished dental models to labs. This would maximize the utilization of their speed advantage while removing the capital expenditure barrier for customers.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW